Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
Top Cited Papers
Open Access
- 8 June 2010
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 102 (12) , 1724-1730
- https://doi.org/10.1038/sj.bjc.6605714
Abstract
Background: Methods: Results: Conclusion:Keywords
This publication has 29 references indexed in Scilit:
- MEK1 mutations confer resistance to MEK and B-RAF inhibitionProceedings of the National Academy of Sciences, 2009
- Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449New England Journal of Medicine, 2009
- V600E BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathwayProceedings of the National Academy of Sciences, 2009
- Integrating BRAF/MEK inhibitors into combination therapy for melanomaBritish Journal of Cancer, 2009
- Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in MelanomaCancer Research, 2008
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activityProceedings of the National Academy of Sciences, 2008
- Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levelsBritish Journal of Cancer, 2007
- Targeted cancer therapyNature, 2004
- The RAF proteins take centre stageNature Reviews Molecular Cell Biology, 2004
- Mutations of the BRAF gene in human cancerNature, 2002